X4 Pharmaceuticals
X4 Pharmaceuticals
XFOR
NASDAQ
0.31
USD
-3.13%
About
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy.
It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 862.8K |
| Three Month Average Volume | 42.3M |
| High Low | |
| Fifty-Two Week High | 1.6 USD |
| Fifty-Two Week Low | 0.5311 USD |
| Fifty-Two Week High Date | 03 Apr 2024 |
| Fifty-Two Week Low Date | 02 Jul 2024 |
| Price and Volume | |
| Current Price | 0.7 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.89% |
| Thirteen Week Relative Price Change | -35.24% |
| Twenty-Six Week Relative Price Change | -36.97% |
| Fifty-Two Week Relative Price Change | -56.36% |
| Year-to-Date Relative Price Change | -29.50% |
| Price Change | |
| One Day Price Change | 1.04% |
| Thirteen Week Price Change | -30.69% |
| Twenty-Six Week Price Change | -30.69% |
| Five Day Price Change | -6.67% |
| Fifty-Two Week Price Change | -45.31% |
| Year-to-Date Price Change | -16.52% |
| Month-to-Date Price Change | -12.51% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.30519 USD |
| Book Value Per Share (Most Recent Quarter) | 0.56155 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.20156 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.39671 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.61838 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00283 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.56895 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.08568 USD |
| Normalized (Last Fiscal Year) | -0.56895 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.56895 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.0865 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.56895 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 0.08568 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.68215 USD |
| Cash Per Share (Most Recent Quarter) | 1.00332 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.5666 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 0.09064 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.60085 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -11,790 |
| Cash Flow Revenue (Trailing Twelve Months) | -21,258 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 3,148.85% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -13,279.90% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | 52.40% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -3,303.55% |
| Operating Margin (5 Year) | -13,083.43% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | 3,131.79% |
| Net Profit Margin (5 Year) | -13,288.93% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -49.06% |
| Tangible Book Value (5 Year) | 9.33% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 12.03% |
| Total Debt (5 Year) | 47.21% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 237.01% |
| EPS Change (Trailing Twelve Months) | 108.20% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -93,724,000 |
| Net Debt (Last Fiscal Year) | -59,646,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | 210 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 8 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 7 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 7 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 7 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 8 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 107 |
| Long Term Debt to Equity (Most Recent Quarter) | 79 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | 6 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 2 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -96,572,000 |
| Free Cash Flow (Trailing Twelve Months) | -119,685,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 107 |
| Total Debt to Equity (Most Recent Quarter) | 79 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -66.81% |
| Return on Assets (Trailing Twelve Months) | 9.18% |
| Return on Assets (5 Year) | -61.53% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -161.67% |
| Return on Equity (Trailing Twelve Months) | 21.77% |
| Return on Equity (5 Year) | -110.33% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -78.53% |
| Return on Investment (Trailing Twelve Months) | 10.59% |
| Return on Investment (5 Year) | -69.20% |